Epstein Secrets

ION REPORT As of Julie 2o, 2011 CONCLUSION Based on the information provided and the analysis conducted, and subject to the attached Statement of Limiting Conditions, it is our opinion that one common share of the Company as of the Valuation Date should be valued as follows: $0.77 (rounded) ZERO DOLLARS AND SEV

511,388 516,110 517,399 518,616 519,733 Full.year caprx ar % of rnwnme 3.4% 1.4% 1.4% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% Remonahlenem Cheek Guideline Company Indications 0.6% to 8.7% A•crap: 2.9% Median 2.2% 35 EFTA00307430 F: F. ge"liAiAri 0000,AZA4g 00,0, 20.122q4 _zn„

ION REPORT As of Julie 2o, 2011 CONCLUSION Based on the information provided and the analysis conducted, and subject to the attached Statement of Limiting Conditions, it is our opinion that one common share of the Company as of the Valuation Date should be valued as follows: $0.77 (rounded) ZERO DOLLARS AND SEV

511,388 516,110 517,399 518,616 519,733 Full.year caprx ar % of rnwnme 3.4% 1.4% 1.4% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% Remonahlenem Cheek Guideline Company Indications 0.6% to 8.7% A•crap: 2.9% Median 2.2% 35 EFTA00307329 F: F. ge"liAiAri 0000,AZA4g 00,0, 20.122q4 _zn„

ION REPORT As of Julie 2o, 2011 CONCLUSION Based on the information provided and the analysis conducted, and subject to the attached Statement of Limiting Conditions, it is our opinion that one common share of the Company as of the Valuation Date should be valued as follows: $0.77 (rounded) ZERO DOLLARS AND SEV

511,388 516,110 517,399 518,616 519,733 Full.year caprx ar % of rnwnme 3.4% 1.4% 1.4% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% Remonahlenem Cheek Guideline Company Indications 0.6% to 8.7% A•crap: 2.9% Median 2.2% 35 EFTA00307228 F: F. ge"liAiAri 0000,AZA4g 00,0, 20.122q4 _zn„